Drug Overview 2018: Invega Sustenna/Invega Trinza (Paliperidone Palmitate; Johnson & Johnson) - ResearchAndMarkets.com

DUBLIN--()--The "Drug Overview: Invega Sustenna/Invega Trinza" report has been added to ResearchAndMarkets.com's offering.

Invega Sustenna and Invega Trinza (paliperidone palmitate; Johnson & Johnson) are long-acting injectable formulations developed by Johnson & Johnson, using with Alkermes's technology.

The drugs contain paliperidone, a metabolite of the atypical antipsychotic Risperdal (risperidone; Johnson & Johnson). Similarly to Risperdal, Invega Sustenna and Invega Trinza block the dopamine receptors D2 and the serotonin receptors 5-HT2A, helping to alleviate schizophrenia symptoms.

In the US, Invega Sustenna was approved for treatment of schizophrenia in July 2009, and for the treatment of schizoaffective disorder in November 2014. In the EU and Japan, Invega Sustenna is marketed under the brand name Xeplion. It was approved in March 2011 in Europe, and in Japan in September 2013. The three-month formulation Invega Trinza was first approved in the US in May 2015, and in the EU in May 2016. Johnson & Johnson retains all marketing rights to the franchise across the US, Japan, and EU.

Key Topics Covered

  1. Drug Overview
  2. Product Profiles
  3. Invega Sustenna/Invega Trinza: Schizophrenia

List of Figures
Figure 1: Invega Sustenna/Invega Trinza for schizophrenia - SWOT analysis
Figure 2: Drug assessment summary of Invega Sustenna/Invega Trinza for schizophrenia
Figure 3: Drug assessment summary of Invega Sustenna/Invega Trinza for schizophrenia
Figure 4: Invega Sustenna sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017-26
Figure 5: Invega Trinza sales for schizophrenia across the US and five major EU markets, by country, 2017-26

List of Tables
Table 1: Invega Sustenna/Invega Trinza drug profile
Table 2: Invega Sustenna pivotal trial data in schizophrenia
Table 3: Invega Trinza pivotal trial data in schizophrenia
Table 4: Invega Sustenna sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 5: Invega Trinza sales for schizophrenia across the US and five major EU markets, by country ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/research/n9px48/drug_overview?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related Topics: Mental Disorders Drugs, Schizophrenia Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related Topics: Mental Disorders Drugs, Schizophrenia Drugs